Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

Trial Profile

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH
  • Sponsors Eli Lilly and Company; ImClone Systems
  • Most Recent Events

    • 07 Jun 2022 Results of pooled analysis of two studies (REACH & REACH-2) assessing efficacy and safety of ramucirumab in Chinese patients (including patients from mainland China, Hong Kong, and Taiwan), presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Mar 2022 Results assessing prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP {greater than or equal to}400 ng/mL from the Phase III REACH and REACH-2 randomized trials, published in the Clinical Cancer Research.
    • 08 Jun 2021 Results assessing prognostic factors in patients with AFP ≥400 ng/mL and predictors of clinical benefit to ramucirumab in an individual participant data meta-analysis of the REACH and REACH-2 Phase III trials, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top